

Dr. Armando Patrizio

Place of Birth:

Naples, Italy

Citizenship:

Dual: Italian and U.S.A.

Education:

2008 – 2014

M.D. (110/110, Summa Cum Laude)

Faculty of Medicine and Surgery

University of Siena, Siena, Italy

2003 – 2008

Diploma (98/100)

Classical Lyceum

Montepulciano, Siena, Italy

Graduate and Post-graduate Training:

2015 - present

Residency in Internal Medicine, graduating class of 2020

University of Pisa , University Hospital

Pisa, Italy

2013 – 2015

Internship in Endocrinology and Metabolism, Thyroid Center

Mentor: Prof Furio Pacini M.D.

Faculty of Medicine and Surgery

University of Siena

Siena, Italy

Professional Experience:

Sept 2019 - Jan 2020

Visiting Fellow

Division of Endocrinology and Diabetes,

Montefiore Medical Center - Albert Einstein College of Medicine

New York City, NY, USA

2015

Physician, Family Medicine Service

South-East District of Tuscany,

National Health System, Italy

Research Experience:

2018 – present

Sub Investigator

Clinical Study “A Phase 3, Randomized, Double-Masked,

Placebo –Controlled, Parallel-Group, Multicenter Study Evaluating

Teprotumumab (HZN-001) Treatment in Subjects with Active

Thyroid Eye Disease”

2018 – present **Sub Investigator**
Clinical Study “ Multicenter, Safety and Efficacy, Open-Label
Extension Study Evaluating Teprotumumab (HZN-001) Treatment
in Subjects with Active Thyroid Eye Disease”

2016 – present **Research Fellow**
Immune - Endocrine and Thyroid Units,
Mentor: Prof Alessandro Antonelli M.D.
University of Pisa
Pisa, Italy

Certifications and Licensures:

2020 **ECFMG certificate**
2019 **USMLE step 2 CS**
2019 **SIUMB National Diploma in Clinical Ultrasonography**
2018 **ICH-GCPs training**
2018 **USMLE Step 2 CK**
2017 **USMLE Step 1**
2015 – present **Italian Medical Licensure, Siena Medical Board, #4873**

Professional Memberships and Affiliations:

2019 – present Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB)
2015 – present Member of Siena Medical Board, Italy
2015 – present Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti
(FADOI), Italy

Oral Presentation:

*Patients Thyroidectomized for Thyroid Cancer in Treatment with Oral Liquid L-Thyroxine (L-T4)
Formulation*, World Congress on Thyroid Cancer, 20-22 June 2019, Rome, Italy.

*Sorafenib induces iodine uptake and hyperthyroidism in a patient with dedifferentiated papillary
thyroid cancer*, 9th Rome Thyroid Cancer Forum, 19th June 2019, Rome, Italy. (**Selected as best
case report**)

Publications:

Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, **Patrizio A**, Gonnella D, Giusti C,

Virili C, Centanni M, Shoenfeld Y, Ferrari SM. *Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy*. Best Pract Res Clin Endocrinol Metab. 2020 Feb 4;101388. doi: 10.1016/j.beem.2020.101388.Review.

Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, **Patrizio A**, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. *Novel treatments for anaplastic thyroid carcinoma*. Gland Surg. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18. Review.

Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Ruffilli I, **Patrizio A**, Materazzi G, Antonelli A. *Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes*. Cancer Manag Res. 2019 Aug 21;11:7893-7907. doi: 10.2147/CMAR.S127848. eCollection 2019.

Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, Paparo SR, **Patrizio A**, Mazzi V, Varricchi G, Marone G, Antonelli A. *Immune and Inflammatory Cells in Thyroid Cancer Microenvironment*. Int J Mol Sci. 2019 Sep 7;20(18). pii: E4413. doi: 10.3390/ijms20184413. Review

Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo SR, **Patrizio A**, Mazzi V, Colaci M, Giuggioli D, Ferri C, Antonelli A. *Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?* J Immunol Res. 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960. eCollection 2019. Review

Antonelli A, Ferrari SM, Elia G, **Patrizio A**, Fallahi P. *Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up*. Gland Surg. 2019 Jun;8(3):298-300. doi: 10.21037/gs.2019.05.05

Ferrari SM, Ruffilli I, Elia G, Ragusa F, Paparo SR, **Patrizio A**, Mazzi V, Antonelli A, Fallahi P. *Chemokines in hyperthyroidism*. J Clin Transl Endocrinol. 2019 May 17;16:100196. doi: 10.1016/j.jcte.2019.100196. eCollection 2019 Jun. Review.

Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, **Patrizio A**, Galdiero MR, Baldini E, Ulisse S, Marone G, Antonelli A. *Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies*. Int J Mol Sci. 2019 May 24;20(10). pii: E2560. doi:10.3390/ijms20102560. Review.

Ferrari SM, La Motta C, Elia G, Ragusa F, Ruffilli I, Quattrini L, Paparo SR, Piaggi S, **Patrizio A**, Ulisse S, Baldini E, Materazzi G, Fallahi P, Antonelli A. *Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration*. Front Endocrinol (Lausanne). 2018 Dec 18;9:764. doi: 10.3389/fendo.2018.00764. ECollection 2018.

Fallahi P, Ferrari SM, Materazzi G, Ragusa F, Ruffilli I, **Patrizio A**, Miccoli P, Antonelli A. *Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study*. Laryngoscope Investig Otolaryngol. 2018 Oct 3;3(5):405-408. doi: 10.1002/lio2.186. eCollection 2018 Oct.

Fallahi P, Foddìs R, Elia G, Ragusa F, **Patrizio A**, Benvenega S, Cristaudo A, Antonelli A, Ferrari SM. *CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide*. Mol Med Rep. 2018 Aug;18(2):1798-1803. doi: 10.3892/mmr.2018.9121. Epub 2018 Jun 1.

Fallahi P, Foddìs R, Elia G, Ragusa F, **Patrizio A**, Frenzilli G, Benvenega S, Cristaudo A, Antonelli A, Ferrari SM. *Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells*. Mol Med Rep. 2018 May;17(5):7415-7420. doi: 10.3892/mmr.2018.8764. Epub 2018 Mar 16.

Fallahi P, Foddìs R, Elia G, Ragusa F, **Patrizio A**, Guglielmi G, Frenzilli G, Benvenega S, Cristaudo A, Antonelli A, Ferrari SM. *Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide*. Mol Med Rep. 2018 May;17(5):6914-6918. doi: 10.3892/mmr.2018.8712. Epub 2018 Mar 9.

Fallahi P, Foddìs R, Elia G, Ragusa F, **Patrizio A**, Benvenega S, Cristaudo A, Antonelli A, Ferrari SM. *Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells*. Oncol Rep. 2018 May;39(5):2422-2426. doi: 10.3892/or.2018.6307. Epub 2018 Mar 8.

Ferrari SM, Bocci G, Di Desidero T, Ruffilli I, Elia G, Ragusa F, Fioravanti A, Orlandi P, Paparo SR, **Patrizio A**, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. *Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo*. Oncol Rep. 2018 May;39(5):2306-2314. doi: 10.3892/or.2018.6305. Epub 2018 Mar 8.

Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, **Patrizio A**, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. *Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo*. Oncol Rep. 2018 May;39(5):2225-2234. doi: 10.3892/or.2018.6306. Epub 2018 Mar 8.

08-04-2020

Date

Signature